Loading
Proven treatments, genomic tests and timely referrals routinely fail to reach the patients who qualify for them. Public trial networks such as the NCTN groups, EORTC and the UK NIHR portfolio would have to spend at least 10% of their funding on cluster-randomised or stepped-wedge trials of how to close that gap, cheap studies that use routine data.
Public trial networks (the NCTN groups, EORTC, UK NIHR portfolio) would be required to allocate at least 10% of funding to implementation trials: cluster-randomised or stepped-wedge studies of how to raise guideline-concordant care, genomic testing rates, timely referral, geriatric assessment and survivorship follow-up. These trials are cheap per patient, use routine data and address a gap that observational studies put at tens of thousands of avoidable deaths a year in high-income countries alone.
Shares NCCN Guidelines, ESMO Clinical Practice Guidelines & MCBS, Fragmented care and guideline gaps.
Shares Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials, Geriatric assessment, Funding follows fashion, not burden.
Shares NCCN Guidelines, ESMO Clinical Practice Guidelines & MCBS.
Shares NCCN Guidelines, ESMO Clinical Practice Guidelines & MCBS.
Shares NCCN Guidelines, ESMO Clinical Practice Guidelines & MCBS.
Shares NCCN Guidelines, ESMO Clinical Practice Guidelines & MCBS.
Shares Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials, Funding follows fashion, not burden.